PMID- 23637322
OWN - NLM
STAT- MEDLINE
DCOM- 20140124
LR  - 20161125
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Linking)
VI  - 40
IP  - 6
DP  - 2013 Jun
TI  - Soluble biomarkers associated with response to treatment with tumor necrosis 
      factor inhibitors in psoriatic arthritis.
PG  - 866-71
LID - 10.3899/jrheum.121162 [doi]
AB  - OBJECTIVE: To identify soluble biomarkers associated with response to therapy 
      with tumor necrosis factor inhibitors (TNFi) in patients with psoriatic arthritis 
      (PsA). METHODS: The study was conducted at a PsA clinic where patients are 
      assessed every 6 months, and serum samples are collected and stored once a year 
      at the time of clinical assessment. Forty patients with active PsA who gave serum 
      samples prior to treatment with TNFi and after at least 3 months of therapy were 
      identified. Patients were classified as TNFi responders if tender joint count was 
      < 3, swollen joint count was 0, and Psoriasis Area and Severity Index score was < 
      4 at the time the second sample was collected. The following biomarkers were 
      tested by ELISA: TNF superfamily 14, matrix metalloprotease-3 (MMP-3), receptor 
      activator of nuclear factor kappa-B ligand, osteoprotegerin, cartilage oligomeric 
      matrix protein (COMP), CPII, C2C and C1-2C, CS-846, and highly sensitive 
      C-reactive protein. Paired t tests and logistic regression was used for 
      statistical analyses. RESULTS: After a mean treatment duration of 11 months with 
      TNFi (etanercept 28 patients, adalimumab 6, golimumab 4, infliximab 2), 29 
      patients were classified as TNFi responders. Baseline level of MMP-3 was 
      independently associated with responder status (OR 1.067 for each 1-unit 
      increase, p = 0.045). A reduction in MMP-3 levels with therapy increased the odds 
      of achieving response (OR 1.213 for each 1-unit change, p = 0.030), whereas a 
      reduction in COMP decreased the odds (OR 0.587, for each 100-unit increase, p = 
      0.039). None of the other biomarkers was associated with response. CONCLUSION: 
      Baseline as well as reduction in serum MMP-3 and increase in serum COMP are 
      independently associated with response to TNFi therapy in patients with PsA.
FAU - Chandran, Vinod
AU  - Chandran V
AD  - Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, 
      Canada.
FAU - Shen, Hua
AU  - Shen H
FAU - Pollock, Remy A
AU  - Pollock RA
FAU - Pellett, Fawnda J
AU  - Pellett FJ
FAU - Carty, Adele
AU  - Carty A
FAU - Cook, Richard J
AU  - Cook RJ
FAU - Gladman, Dafna D
AU  - Gladman DD
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130501
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Cartilage Oligomeric Matrix Protein)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Osteoprotegerin)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 91X1KLU43E (golimumab)
RN  - B72HH48FLU (Infliximab)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/*blood/drug therapy
MH  - Biomarkers/blood
MH  - Cartilage Oligomeric Matrix Protein/blood
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/therapeutic use
MH  - Infliximab
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Osteoprotegerin/blood
MH  - Receptors, Tumor Necrosis Factor/therapeutic use
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
OTO - NOTNLM
OT  - BIOMARKERS
OT  - PSORIASIS
OT  - PSORIATIC ARTHRITIS
OT  - TREATMENT
OT  - TUMOR NECROSIS FACTOR INHIBITORS
EDAT- 2013/05/03 06:00
MHDA- 2014/01/25 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/05/03 06:00 [entrez]
PHST- 2013/05/03 06:00 [pubmed]
PHST- 2014/01/25 06:00 [medline]
AID - jrheum.121162 [pii]
AID - 10.3899/jrheum.121162 [doi]
PST - ppublish
SO  - J Rheumatol. 2013 Jun;40(6):866-71. doi: 10.3899/jrheum.121162. Epub 2013 May 1.